Cancer Research Institute (CRI) shared a post on LinkedIn:
“The Cancer Research Institute is pleased to announce the enrollment of the first patient in the second stage of BR.36 (NCT04093167), a Phase 2/3 clinical trial using circulating tumor DNA (ctDNA) to measure early responses to immunotherapy and guide treatment decisions for advanced lung cancer patients.
This trial underscores the transformative potential of liquid biopsies, not just as a diagnostic tool but also as a guide for personalized cancer care. By identifying patients most likely to benefit from specific treatments, this approach could maximize the effectiveness of immunotherapies and improve outcomes for people living with cancer.
More posts about Cancer Research Institute.